“A Settlement Hearing shall be held before the Court on January 3rd, 2018 before the Honorable David A. Boynton, at the Montgomery County Circuit Court, 50 Maryland Avenue, Rockville, Maryland 20850, to determine whether, inter alia, the proposed Settlement is fair, reasonable, and adequate, and should be finally approved by the Court and whether Plaintiffs Counsel's Fee Award and Plaintiffs Service Award should be finally approved” for Kent Wells v Linda F Powers et al. “The proposed Settlement, if approved by the Court, would fully, finally and forever resolve the Action on the terms set forth in the Stipulation and summarized in this Notice, including the dismissal of the Action with prejudice.”
March 7 -- About 3 million in loans received -- due in 6 months (+ interest) or sooner. Changes in this post made after reading "refinements" from Jerry. March 17 -- 7.5 (Effectively 6.7 million after expenses according to Jerry) million raise. (Closed on March 22nd) March 27 -- DCVax Advanced Method (aka: B+(?)) International Publication Date of International Patent Application for "METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS" -- DD Courtesy of Smokey March 28 -- Yonemura v. Powers recorded conference call. (Stayed to July 28 for "final resolution") March 30 -- Last day for companies at ASCO to get any "late breaking abstract" data in. March 30 -- Dr. Schwartz inaccurately tweets (with glee) NWBO withdrew their NWBO ASCO booths. March 30/31 -- 6 Cognate jobs (with prior various original posting dates) reposted on Monster.com March 31 -- Payment by NWBO due -- 500k (or sooner upon request)(paid) March 31 -- Lerner v. NWBO case dismissed in favor of NWBO. (Approximately 19.3 month old case) (Info: Courtesy of Senti)
April 1 -- Dr. Prins speaks at AACR conference. April 3 -- Job listing: Manager, Validation Services at Cognate Bioservices. April 4 -- Two business days after Lerner suit dismissed and five business days after Yonemura case set for "final resolution" this summer, AF writes hit article against NWBO regarding (no longer existing) partial clinical hold on screening. Additionally, AF criticizes NWBO AACR booth, booth location and Dr. Bosch. Dr. Schwartz also criticizes (and tweets) AACR booth with joy -- claims no one there to answer questions -- Even though AF questioned Dr. Bosch. April 5 -- India FDA approves autologous dendritic therapy for prostate, ovarian, lung and colorectal cancer. (Info courtesy of ForumReader35) April 17 --10K filed April 18 -- Since March 31, five Cognate job postings the listed and/or relisted have either been filled (or simply removed.) April 19 -- Payment by NWBO due -- 2.3 million (some might be due sooner upon request) (paid). April19 -- Payment by board (lenders) on 2.3 million through loan financing. April 19 -- ASCO Titles leaked by ASCO website one day early. http://www.investorvillage.com/smbd.asp?mb=16353&mn=78709&pt=msg&mid=17081359 April 20 -- ASCO titles for Regular and LBA released. No abstracts related to DCVax. April 24 -- Bear attack, preceded over the weekend by unsubstantiated claim of PFS futility. April 25 -- Announcement of loan financing by Board members that occurred on April 19, 2017 to pay off 2.3 million in notes owed.
May 5 -- Since March 31/April 4, seven of seven Cognate job postings listed and/or relisted have either been filled (or perhaps simply removed.) May 5 -- One million dollar loan (aka: equivalent to six-and-a-half million shares). Due on June 30, 2017. (Due Diligence courtesy of Omair92 & Bioaddict ) May 9 -- Likely final vote on FDA Commissioner confirmation -- Due Diligence courtesy of Sentimentstocks. May 9 -- Scott Gottlieb confirmed as new FDA Commisioner. May 10 -- ESMO regular abstract deadline. May 15 -- Woodford Fund confirms it is still holding NWBO in its Patient Capital Trust portfolio as of April 30, 2017. (Due Diligence Courtesy of TiltMyBrain) May 15 -- 1st Quarter 10Q filing due. (Due Diligence reminder courtesy of Kabunushi) May 15 -- 1st Quarter 10Q filed. SentimentStocks pointed out the 10Q notes that NWBO is now moving forward with process validation work. May 17 -- Regular abstracts released by ASCO May 17 -- Notice of exempt offering of securities filed with SEC. May 17 -- UK's NICE confirms developing a guideline on DCVax-L for treating newly diagnosed glioblastoma -- albeit in early stages. Due Diligence Courtesy of CherryTree. May 20 -- Payment by NWBO due -- 2.5 million (paid) May 22, 2017 -- Security Purchase Agreement hold on PFS data release lifted. End of May, or possibly later, rGBM combination trial to initiate. NOW moved to August.
Maybe June or later -- 233 events June 2-6 -- ASCO. LBAs released June 5 -- Dr. Marnix Bosch discusses DCVax at ASCO's Industry Expert Theater @ 3:00. June 5 -- Dr. Marnix Bosch notes currently 231 patient OS events (100 patients still alive), and 233 events expected by mid July 2017. He notes OS eventing is slower than anticipated at this time. Dr. Bosch also notes Investigators already working on a publication for the DCVax-L trial. Median Length of time patients have been enrolled in the DCVax-L trial is 37 months. Dr. Bosch is preparing for a sarcoma trial for DCVax-Direct soon and plans on incorporating approved checkpoint inhibitors in some DCVax-Direct trials. In the Phase I DCVax-Direct trial, 23% of patients exceeded two years OS, and 18% have exceeded 30 months. In the info arm for DCVax-L, 40% of patients lived past about three years in the indeterminate arm and 24% have lived past four years in the same arm. June 12 -- SNO (Society for NeuroOncology) regular abstract deadline. Approx. June 17 -- Deadline to exercise 3 month warrants? Up to $21.6 million cash received (or none at all) June 20 -- Payment by NWBO due -- 5.5 million (Paid) June 22 -- Announcement: "This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondholders entered into in March". (Due Diligence by John, and premonition of sorts by JDHeart smile) June 30 -- Repayment on 1 million dollar loan due.
July 19 -- LBA deadline ESMO July 28 -- Yonemura v. Powers, the parties have reached (stipulated to) a settlement, but the court will not convene a hearing for potential approval thereof until October [31], 2017. This public notice was issued on July 28 in a Federal Court document, even though the settlement stipulation was entered back on May 19, 2017. Due diligence courtesy of Barcode27
August 1 -- No longer Scheduled* start of DCVax-L recurrent GBM combo trial. (*Still has not initiated as of August 8) This scheduled start date was changed to October 1 (change was made on Aust 17) Due Diligence: SBNYC Aug 1 -- SITC regular abstract deadline. Aug 5 -- Last screening/recruitment was TWO YEARS (24 months) prior to this date in the phase III DCVax-L trial. Aug 7 -- 2 recent financings raise approximately 3.7 million dollars, likely increasing the fully diluted share count north of 415 million* (*my estimate.) August 8 -- additional financial raises. See August 21 for grand totals. August 21 -- 10Q filed. "As of August 21, 2017, the total number of shares of common stock, par value $0.001 per share, outstanding was 295,253,044." "Potentially Dilutive Securities" 192,778,000 (see page 20) This apparently results in about 488 million fully diluted? NWBO is winding up Cognate manufacturing in Germany and Israel, however, it is continuing to expand Advent Bioservices (formerly named Cognate) manufacturing in the UK. Cognate in the United States has changed its payment arrangement with NWBO whereby it only exacts per patient batch -- without charging for costs such as empty clean rooms during slow times. August 26 -- Approximately 10 million in warrants expire reducing fully diluted count to about 478 million? Aug 31 -- August 31, 2017 11:45 Dendritic Cell Immunotherapy for Solid Tumors, Marnix Bosch, Ph.D., CTO, Northwest Biotherapeutics (Due Diligence Courtesy of Forum Redaer)
Sept -- DCVax-L adjuvant trial estimated trial completion date. (postponed to October 2018) Due Diligence: Exwannabe Sept 1 -- Late Breaking Abstracts Due for SNO Conference. (Society for NeuroOncology) (Due Diligence courtesy of various posters) Sept 5 UCLA paper reports significant progress in human and animal imaging studies to distinguish psPD from real progression in GBM. Perhaps more importantly, this imaging technology can also help determine whether there are tumor infiltrating lymphocytes and whether there is lymphocyte activity in peripheral nodes, thereby providing a noninvasive tool to help determine immune response. The human study was conducted in nonresected recurrent tumors. (Note: The phase II DCVax-L monotherapy & combination trial will be in a slightly easier to treat population where recurrent tumors are first resected -- rather than the nonresected recurrent population in the aforementioned pilot study.) (Note: Drugs like Avastin may mask this new imaging technology, but Avastin is more often used in inoperable recurrent cases, which should not be the case for new enrollees in the phase II recurrent GBM trial.) Finally, the pilot study demonstrated there is TIL and peripheral node activity/increase in response to DCVax-L & DCVax-L + Checkpoint Inhibitor -- although Avastin appears to mask TIL activity in humans. Sept 7 -- Approximately 3 million (+ interest) in loan repayments by NWBO due (or sooner upon request). Sept 8-12 ESMO Congress Sept 14 -- SITC late breaking abstract deadline. Sept 27 -- NWBO presentation at SMI Cancer Vaccine conference has been cancelled per September 25, 2017 8K, because NWBO is "ANTICIPATING DISCLOSURE OF INTERIM BLINDED DATA."
October 1 (Postponed to January 1, 2018....third postponement) -- start of DCVax-L monotherapy and combo trial with Nivolumab (aka: Opdivio) in Recurrent GBM. Due Diligence: SBNYC October 17, 2017 -- NWBO lease out 275,000 sq ft building in Sawston, UK for 3.5 to 5 years to a commodity storage and distribution firm domiciled in the UK. Lease Includes Substantial Refurbishment and Approximately $6 Million Revenues Over 5 Years. October 20, 2017 -- Company conducted small financing to obtain $500,000.00 semolians. Of note was fact that NWBO appeared at or very near the end of its 450 million dollar shelf limit (perhaps currently at 443 million), but NWBO still retains 40 million in preferred shares that are eligible for issuance. October 25, 2017 -- Company announces four lawsuits against it are in two cases dismissed, and in the other two pending dismissal with no further costs to investors. (A fifth smaller lawsuit (Chardan versus NWBO) demanding 500,000 from NWBO is still outstanding.) October 27, 2017 -- NWBO filed letter with the Court still pursuing dismissal of Chardan case. Due Diligence: Barcode27 October 31, 2017 -- I'd expect this date to be the latest cutoff for new shares purchased to allow purchaser to vote those shares in any NWBO December 2017 shareholder meeting that might be scheduled. This is purely speculation on my part.
First week of November: 24 months since last patient enrollment. Approximately 27 months since last patient diagnosed. (Source for date initiation: Dr. Marnix Bosch presentation at ASCO on June 5, 2017) November 1, 2017 -- Cognate increasing job listings. Seven over last month, and four of those added today. November 3, 2017 deadline for companies wishing to submit late breaking abstract data for December 7-10 ESMO Immuno Oncology conference in Switzerland. November 3, 2017 Dr. Scott Gottlieb, the commissioner of the Food and Drug Administration, will appear at a National Press Club Headliners Luncheon on Friday, Nov. 3 to discuss the FDA’s agenda and related issues. Livestream will begin at 1:00 pm EST, www.press.org/events/npc-headliners-luncheon-fda-commissioner-dr-scott-gottlieb Due Diligence: Xena and Sentiment November 8-12 -- NWBO Exhibit (Booth) at Society for Immunotherapy of Cancer conference. November 13 -- Chardan against NWBO -- Parties inform court they would prefer a settlement conference within the next month. In a separate filing, NWBO confirms no publicly held corporation owns 10% or more of its stock. Due Diligence Courtesy of TCTrader and Barcode. November 14 -- ASCO starts receiving abstracts for next year's spring conference. November 14 -- NWBO obtains new registered trademark for DCVAX. Due Diligence: ATLnsider November 14 - 20 -- NWBO files five day extension request for third quarter report. Due Diligence: Jerry and Hodag. November 16, 2017 FDA announces comprehensive regenerative medicine policy framework https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585345.htm and Expedited Programs for Regenerative Medicine Therapies for Serious Conditions https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585414.pdf Among other things, allows companies in some cases to pursue Accelerated Approval based upon data from a "significant" number of clinical trial sites. -- Due Diligence courtesy of SentimentStocks. November 16-19 -- NWBO booth at Society for Neurooncology conference. Due Diligence Courtesy of: Whitewater55 November 23 -- Yonemura case to be dismissed with prejudice. Due Diligence: Sentiment_Stocks and TC_Trader. November 20 -- 10Q filed. Cognate debt to be paid -- settlement agreement for massive share payment (and cash) from NWBO (most cash apparently via investor financing.) Cognate waived its right to recover half the debt owed. There was agreement as of November 20, but the parties had not completed drafting nor signature as of the Nov 20th filing. NWBO, through Advent, signaled it is preparing for DCVax-L production and negotiating contracts for distribution in Europe and the UK. November 30, 2017 -- FDA intends to complete guidance that will make early/accelerated approval easier for therapies that qualify by demonstrating very early survival efficacy data in addition to high safety profile. Expected guidance in January 2018.
December 1 -- As of the date of this update on December 1, 2017 -- The company has not publicly notified investors of any intent to delay previous plan to data lock at about 233 OS, obtain independent analysis and unblind the results. It is assumed by most board members 233OS was already reached sometime in the past -- potentially months ago. December 1 -- (Senate Tax Bill Vote Likely Today. It ran into snag due to its likelihood of increasing deficit by one trillion dollars over 10 years. Newspapers are now reporting Senate has the votes. The Treasury Department’s inspector general is examining whether political considerations interfered with Secretary Steven Mnuchin’s promised analysis of the Republican tax proposal. No longer November 20 -24 -- Republican previous goal for Senate passing tax bill including tax repatriation. Any law passed on tax repatriations could have major impact on accelerating M&A in biotech.) December 2017 -- ASM? (No ASM scheduled in December) December 5-7, 2017 IMMUNOTHERAPY Progress and Clinical Treatments Making an IMPACT on the Next Generation of Immunotherapy | San Diego, CA (It appears from work done by the Ihub board that Dr. Boynton was scheduled to present on December 6th on an unknown topic; however, it appears he has fully withdrawn, and it appears an unrelated speaker now has that time slot. Due Diligence: ATLnsider, Barunuuk and other board members. December 7-10 ESMO Immuno Oncology conference in Switzerland. December 15 -- Congress hopes to have tax reform bill on President's desk. (If passed, this likely means large pharma would have additional repatriation funds for M&A of smaller companies) December 22 -- Tax Bill signed. Big Pharma will repatriate billions and billions. This may start a M&A spree during 2018. December 19 -- Regulation D offering for accredited investors (likely taking fully diluted share count to approximately one billion shares -- however, it should be mentioned the lion's share are closely held) January 1, 2018 -- Previously scheduled start of DCVax-L monotherapy and combo trial with Nivolumab (aka: Opdivio) in Recurrent GBM (Nothing official has been announced as of January3.) [color=red]January 3, 2018 -- Wells versus Powers to be dismissed (leaving only Chardan v. NWBO -- an inconsequential case) For all practical purposes, all meaningful outstanding lawsuits dismissed on or before today. January 23 -- 10:15 a.m. Miami conference: LP will speak: "Achieving both precision targeting and broad spectrum immunotherapy." January 24 -- 4:10 p.m. Miami conference: NWBO: "Challenges of heterogeneous solid tumors: targeting broad spectrum of tumor biomarkers while also precision tailoring to the patient"
February 9, 2018 -- The Seattle Science Foundation will be hosting their 3rd Annual Brain Tumor Management event on February 9, 2018. Due Dilgence Courtesy of Sentiment Stocks.
News 
Market Data 
Discover 
